| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w29206 |
| 来源ID | Working Paper 29206 |
| Markups and Fixed Costs in Generic and Off-Patent Pharmaceutical Markets | |
| Sharat Ganapati; Rebecca McKibbin | |
| 发表日期 | 2021-09-06 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | There is wide dispersion in pharmaceutical prices across countries with comparable quality standards. Under monopoly, off-patent and generic drug prices are at least four times higher in the United States than in comparable English-speaking high income countries. With five or more competitors, off-patent drug prices are similar or lower. Our analysis shows that differential US markups are largely driven by the market power of drug suppliers and not due to wholesale intermediaries or pharmacies. Furthermore, we show that the traditional mechanism of reducing market power – free entry – is limited because implied entry costs are substantially higher in the US. |
| 主题 | International Economics ; Trade ; Health, Education, and Welfare ; Health ; Industrial Organization ; Antitrust ; Industry Studies |
| URL | https://www.nber.org/papers/w29206 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586879 |
| 推荐引用方式 GB/T 7714 | Sharat Ganapati,Rebecca McKibbin. Markups and Fixed Costs in Generic and Off-Patent Pharmaceutical Markets. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w29206.pdf（876KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
